登录 | 注册    关注公众号  
微信公众号
搜索
 >  Cell>GCGR >CHEK-ATF103

Human GCGR (Luc) HEK293 Reporter Cell

For research use only.

  1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
  2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
  3. Comprehensive application data to support assay development and validation
  4. Full tracible record, stringent quality control and validated cell passage stability
  5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
  6. Global commercial license assistance whenever regulatory filing is required

描述(Description)

The Human GCGR (Luc) HEK293 Reporter Cell was engineered to not only express CREB signaling response element, but also express the receptor full length human GCGR (Gene ID: 2642), which can drive luciferase expressing systems by GCGR agonists or Glucagon stimulation. In the absence of agonist or Glucagon, the GCGR receptor is not activated and luminescence signal is low. In the presence of agonist or Glucagon, the GCGR pathway-activated luminescence can be detected in a dose-dependent manner.

应用说明(Application)

• Screen for agonists that can bind and activate GCGR.

GCGR Assay Principles

生长特性(Growth Properties)

Adherent

筛选标记(Selection Marker)

Puromycin (2 μg/mL) + Hygromycin (20 μg/mL)

培养基(Culture Medium)

DMEM medium + 10% FBS

冻存液(Freeze Medium)

Serum-free cell cryopreservation medium

装量(Quantity)

1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

存储(Storage)

Frozen in liquid nitrogen.

支原体检测(Mycoplasma Testing)

Negative

无菌检测(Sterility Testing)

Negative

使用说明(Instructions for Use)

See data sheet for detailed culturing and assay protocol.

 

Receptor Assay

GCGR FACS

Expression analysis of human GCGR on Human GCGR (Luc) HEK293 Reporter Cell by FACS.
Cell surface staining was performed on Human GCGR (Luc) HEK293 Reporter Cell or negative control cell using Alexa Fluor® 488-labeled anti-human GCGR antibody.

Protocol

 

Application

GCGR APPLICATION

Bioactivity analysis of human GCGR agonist (RLU).
This reporter cell was incubated with serial dilutions of Retatrutide (a triple agonist peptide of GCGR, GIPR and GLP-1R). The EC50 of Retatrutide was approximately 0.024 nM.

Protocol

GCGR APPLICATION

Bioactivity analysis of human GCGR agonist (FOLD).
This reporter cell was incubated with serial dilutions of Retatrutide (a triple agonist peptide of GCGR, GIPR and GLP-1R). The max induction fold was approximately 79.93.

Protocol

 

Passage Stability

GCGR PASSAGE

Passage stability analysis by Signaling Bioassay.
The continuously growing Human GCGR (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of Retatrutide (a triple agonist peptide of GCGR, GIPR and GLP-1R). Retatrutide stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 7-20.

Protocol

如有相关细胞池需求请联系我们

 

背景(Background)

G-protein coupled receptor for glucagon that plays a central role in the regulation of blood glucose levels and glucose homeostasis. Regulates the rate of hepatic glucose production by promoting glycogen hydrolysis and gluconeogenesis. Plays an important role in mediating the responses to fasting. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Promotes activation of adenylate cyclase. Besides, plays a role in signaling via a phosphatidylinositol-calcium second messenger system.

 

Limited Use&License Disclosure

  1. This cell line is provided for research use only. It is neither intended for any animal or human therapeutic use nor for any direct human in vivo use. You are restricted to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
  2. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
  3. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
  4. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order.cn@acrobiosystems.com for further details.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
GCGR靶点信息
英文全称:Glucagon receptor
中文全称:胰高血糖素受体
种类:Homo sapiens
上市药物数量:5详情
临床药物数量:33详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定